# Systematic Use of DDAVP to Prevent Serum Sodium Overcorrection in Severe Hyponatremia

> **NCT06020495** · PHASE3 · RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 260 (estimated)

## Conditions studied

- Hyponatremia

## Interventions

- **DRUG:** DDAVP
- **DRUG:** Standard hyponatremia treatment

## Key facts

- **NCT ID:** NCT06020495
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-17
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-11-30
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2025-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06020495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06020495, "Systematic Use of DDAVP to Prevent Serum Sodium Overcorrection in Severe Hyponatremia". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06020495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*